Please login to the form below

Not currently logged in
Email:
Password:

UCB launches epilepsy campaign

UCB has launched 'Epilepsy In Our Time' – a video campaign to mark the first European Epilepsy Day

UCB has launched 'Epilepsy In Our Time' – a video campaign to mark the first European Epilepsy Day.

The annual event is co-ordinated by the International Bureau for Epilepsy (IBE), an organisation comprising epilepsy associations from across the world, and the International League Against Epilepsy (ILAE), a global organisation representing healthcare professionals working in the field of epilepsy.

It is scheduled to be held each year on the second Monday in February, with plans to raise awareness of the condition across Europe.

UCB's campaign involves online video diaries made by people living with epilepsy. The company said the diaries provide an insight into modern perceptions of the condition, as well as what epilepsy is like to live with.

People involved in the series of videos include Marion, who won an Olympic silver medal in cycling for France in 2000, and Julie and David, whose 11-year-old son Dominic has severe epilepsy.

UCB has launched 'Epilepsy In Our Time'


Commenting on the 'Epilepsy In Our Time' campaign, Mike Glynn, president, IBE, said: "Epilepsy is the most common serious brain disorder, affecting 6 million people in Europe, but is an under-recognised and poorly understood condition, often leaving individuals exposed to stigma and prejudice. We welcome any new initiative that raises awareness and understanding of epilepsy."

European Epilepsy Day follows the annual Latin American Epilepsy Day held on September 9, with the IBE saying it plans to hold an annual day in each of its seven regions.

Plans for an international epilepsy day have been postponed until the World Health Organization is able to offer its support, according to the IBE.

Belgium-based biopharma UCB specialises in developing therapies for severe central nervous system or immunological disorders, and has several epilepsy drugs approved for marketing, including Vimpat (lacosamide) and Keppra (levetiracetam).

14th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....